Bank Of New York Mellon Corp Metacrine, Inc. Transaction History

Bank Of New York Mellon Corp

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	BUY	$0.35 - $0.46 $71,408 - $93,850	204,023 New	204,023 $91,000
Q2 2022 Aug 15, 2022	SELL	$0.36 - $0.63 $505 - $883	-1,403 Reduced 0.68%	205,616 $103,000
Q1 2022 May 11, 2022	BUY	$0.43 - $0.7 $84,249 - $137,150	195,929 Added 1766.72%	207,019 $126,000
Q1 2021 May 13, 2021	BUY	$6.2 - $11.0 $68,758 - $121,990	11,090 New	11,090 $68,000

Ticker MTCR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 42,569,500
Description
Metacrine, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing therapies for patients with gastrointestinal diseases. It is developing MET642, which has completed Phase I clinical trial for the treatment of ulcerative colitis. Metacrine, Inc. was incorporated in 2014 and is headquartered in San Diego, California.

Get notified when there are updates to the investment portfolio of Bank Of New York Mellon Corp, based on Form 13F filings with the SEC.

Stay updated on Bank Of New York Mellon Corp with notifications on news.